Aberrant activity of CDK4/cyclin D1 has been implicated in several cancers, and blocking CDK4/cyclin D1 activity with Ox-1 was previously shown to be an effective anticancer therapy for pRb+ solid tumors [22]. Here, CDK4 is linked to cancer.